Publication In Focus: Using 40-GEP for enhanced metastatic risk assessment in cutaneous squamous cell carcinoma
Clinicians use clinicopathologic factors to determine risk for cutaneous squamous cell carcinoma (cSCC) disease progression. However, traditional methods miss pinpointing many patients who experience metastasis and sometimes categorize patients as at risk who do not develop metastasis, indicating that additional tools are needed. A molecular test, the 40-gene expression profile (40-GEP), was developed to predict metastatic risk based on the biology of the tumor. This publication investigates 40-GEP for accurately identifying patients’ risk of metastasis.
In this Publication In Focus feature, hear Dr Sherrif Ibrahim (University of Rochester Medical Center, NY, USA) discuss the recent publication in a podcast, as well as visually understanding the methods and results through the infographic. Finally, the Oncology Central article feature summarises the article in a short format.
FEATURES
Podcast: Using 40-GEP to enhance metastatic risk assessments in cutaneous squamous cell carcinoma
In this episode of OCTalks, Dr Ibrahim discusses cSCC and current metastatic risk assessments used for staging the disease, as well as their recent study investigating 40-GEP.
Infographic: Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile testThis infographic visualizes the studies key objectives, study design and outcomes.
This article feature highlights the key points of the study in a short summary.